In this observational cohort study, 10 patients with extensive or treatment-refractory AIDS-associated Kaposi sarcoma were treated with peginterferon alfa-2a. Tumor responses were observed in 9 patients with a median progression-free survival of 645 days. Peginterferon alfa-2a could be an effective therapy for extensive or treatment-resistant Kaposi sarcoma.

, , , ,,
Clinical Infectious Diseases
Department of Internal Medicine

Rokx, C., van der Ende, M., Verbon, A., & Rijnders, B. (2013). Peginterferon Alfa-2a for AIDS-associated kaposi sarcoma: Experience with 10 patients. Clinical Infectious Diseases, 57(10), 1497–1499. doi:10.1093/cid/cit517